We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
VWR Posts Inline Earnings in Q2, Revenues Beat the Mark
Read MoreHide Full Article
VWR Corporation reported second-quarter 2016 adjusted earnings per share (EPS) of 42 cents, reflecting a 23.5% rise from the year-ago quarter. The quarter’s earnings, however, remained at par with the Zacks Consensus Estimate. We note that, strong top-line growth prompted the year-over-year growth in earnings.
Including one-time items, the company reported second-quarter 2016 net EPS of 32 cents, a 128.6% surge year over year.
Revenues in the reported quarter were up 6.3% year over year at $1.15 billion. Revenues edged past the Zacks Consensus Estimate of $1.14 billion. Foreign exchange headwinds impacted revenues by 0.3% year over year. On an organic basis, revenues increased 4.4%, while recent acquisitions boosted revenues by 2.2%.
Revenues in the Americas totalled $694.9 million, up 6.6% year over year (up 3.9% organically) in the second quarter. The top-line increase was supported by strong biopharma performance, on high single digits on growth in large pharma, biotech, medical devices and sales to CRO-customers.
EMEA-APAC revenues in the second quarter were $454.6 million, up 5.9% year over year (up 5.1% year over year on an organic basis), on strong sales to biopharma and industrial customers. EMEA-APAC performance was also benefitted from a shift in the timing of Easter.
VWR reported a gross margin of 28.1%, up 53 basis points (bps) year over year, on account of a stable pricing environment, favorable product mix and solid growth in private label and services. Sales, general and administrative expenses rose 8.1% to $238.8 million. VWR posted operating income of $84.6 million in the reported quarter, reflecting a 9% rise from the year-ago quarter. Accordingly, operating margin expanded 18 bps to 7.4% in the quarter under review.
VWR exited the second quarter with cash and cash equivalents of $112.9 million, down from $129.7 million at the end of the first quarter. Year-to-date operating cash flow was $119.6 million, compared with $97.1 million in the year-ago period.
VWR reiterated its 2016 earnings guidance of adjusted EPS in the band of $1.68–$1.74 (annualized growth of 11% to 15%).
Our Take
VWR posted a moderate second-quarter with earnings in line with the Zacks Consensus Estimate and revenues ahead of the mark. Segment-wise, management witnessed strong sales growth in both Americas as well as the EMEA-APAC region, accompanied by strong growth in equipment and instrumentation. The extent of currency fluctuations on the company’s EMEA-APAC sales was low in the second quarter. On the profitability front, VWR posted slightly improved margin figures in spite of the competitive landscape.
Zacks Rank & Key Picks
Currently, the company bears a Zacks Rank #4 (Sell). Better-ranked medical stocks are Align Technology Inc. (ALGN - Free Report) , AmerisourceBergen Corporation and DENTSPLY International Inc. (XRAY - Free Report) . All the three stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
VWR Posts Inline Earnings in Q2, Revenues Beat the Mark
VWR Corporation reported second-quarter 2016 adjusted earnings per share (EPS) of 42 cents, reflecting a 23.5% rise from the year-ago quarter. The quarter’s earnings, however, remained at par with the Zacks Consensus Estimate. We note that, strong top-line growth prompted the year-over-year growth in earnings.
Including one-time items, the company reported second-quarter 2016 net EPS of 32 cents, a 128.6% surge year over year.
Revenues in the reported quarter were up 6.3% year over year at $1.15 billion. Revenues edged past the Zacks Consensus Estimate of $1.14 billion. Foreign exchange headwinds impacted revenues by 0.3% year over year. On an organic basis, revenues increased 4.4%, while recent acquisitions boosted revenues by 2.2%.
Revenues in the Americas totalled $694.9 million, up 6.6% year over year (up 3.9% organically) in the second quarter. The top-line increase was supported by strong biopharma performance, on high single digits on growth in large pharma, biotech, medical devices and sales to CRO-customers.
EMEA-APAC revenues in the second quarter were $454.6 million, up 5.9% year over year (up 5.1% year over year on an organic basis), on strong sales to biopharma and industrial customers. EMEA-APAC performance was also benefitted from a shift in the timing of Easter.
VWR reported a gross margin of 28.1%, up 53 basis points (bps) year over year, on account of a stable pricing environment, favorable product mix and solid growth in private label and services. Sales, general and administrative expenses rose 8.1% to $238.8 million. VWR posted operating income of $84.6 million in the reported quarter, reflecting a 9% rise from the year-ago quarter. Accordingly, operating margin expanded 18 bps to 7.4% in the quarter under review.
VWR exited the second quarter with cash and cash equivalents of $112.9 million, down from $129.7 million at the end of the first quarter. Year-to-date operating cash flow was $119.6 million, compared with $97.1 million in the year-ago period.
VWR CORP Price, Consensus and EPS Surprise
VWR CORP Price, Consensus and EPS Surprise | VWR CORP Quote
Outlook
VWR reiterated its 2016 earnings guidance of adjusted EPS in the band of $1.68–$1.74 (annualized growth of 11% to 15%).
Our Take
VWR posted a moderate second-quarter with earnings in line with the Zacks Consensus Estimate and revenues ahead of the mark. Segment-wise, management witnessed strong sales growth in both Americas as well as the EMEA-APAC region, accompanied by strong growth in equipment and instrumentation. The extent of currency fluctuations on the company’s EMEA-APAC sales was low in the second quarter. On the profitability front, VWR posted slightly improved margin figures in spite of the competitive landscape.
Zacks Rank & Key Picks
Currently, the company bears a Zacks Rank #4 (Sell). Better-ranked medical stocks are Align Technology Inc. (ALGN - Free Report) , AmerisourceBergen Corporation and DENTSPLY International Inc. (XRAY - Free Report) . All the three stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>